Immupharma PLC - Thermo Fisher CDMO selected for Kapiglucagon pro
This announcement contains inside information for the purposes of the

ImmuPharma PLC
("ImmuPharma" or the "Company")
ImmuPharma selects Thermo Fisher Scientific drug product CDMO for Kapiglucagon program
ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that, following a competitive tender process, it has selected Thermo Fisher Scientific, the world leader in serving science, as its drug product ("DP") and contract development and manufacturing organisation ("CDMO") for its Kapiglucagon program.
Thermo Fisher's Patheon pharma services is a leading global pharmaceutical development and manufacturing organization, supporting pharmaceutical and biotechnology companies from early-stage development through to commercial supply.
The selection of Thermo Fisher represents an important Chemistry, Manufacturing and Controls ("CMC") milestone for the Kapiglucagon program and is expected to support the next stages of pharmaceutical development and IND-enabling preparation.
This development follows the Company's recent announcement regarding the appointment of Bachem AG as API manufacturing partner for the Kapiglucagon program. The program is being advanced through a streamlined development strategy, with ImmuPharma evaluating a potential 505(b)(2) regulatory pathway in
About Kapiglucagon
Kapiglucagon is a proprietary glucagon prodrug being developed for Type 1 diabetes ("T1D") applications, with a focus on overcoming the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings.
ImmuPharma believes Kapiglucagon represents an important strategic opportunity alongside its lead asset, P140. The Company has previously stated that it intends to pursue an accelerated development plan for Kapiglucagon, including evaluation of a 505(b)(2) regulatory pathway, and that the program is supported by the recently approved funding initiative intended to advance the asset over the next two years.
Next steps
The selection of Thermo Fisher is expected to support the DP workstream of the Kapiglucagon CMC program. In parallel, ImmuPharma intends to continue advancing the regulatory and development strategy for Kapiglucagon, including future regulatory interactions and, subject to alignment with health authorities, progression towards IND submission and first-in-human studies.
Dr
"We are pleased to select Thermo Fisher as DP CDMO for the Kapiglucagon program. This represents an important step in strengthening the CMC foundation of the program as we continue to advance Kapiglucagon toward clinical development."
"We are pleased to collaborate with ImmuPharma on the Kapiglucagon program. Our team is committed to helping customers advance innovative therapies by providing the development and manufacturing expertise needed to advance programs efficiently through key development milestones. We look forward to supporting ImmuPharma as the program progresses."
|
For further information please contact:
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk.
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
Kapiglucagon: A Stable Next-Generation Glucagon Prodrug for Diabetes
Kapiglucagon has been developed to address the key pharmaceutical limitations associated with native glucagon. It is a water-soluble glucagon prodrug designed to maintain high stability in aqueous solution while regenerating native glucagon in vivo following subcutaneous administration. Unlike native glucagon, which rapidly aggregates and forms fibrils in solution, Kapiglucagon demonstrates excellent solubility and formulation stability, enabling the development of clean, saline-based formulations that do not clog pump-based delivery systems. This improved physicochemical profile makes Kapiglucagon particularly well suited for continuous or intermittent delivery in advanced diabetes technologies, including next-generation artificial pancreas systems. By combining the therapeutic activity of native glucagon with a formulation that overcomes its inherent instability, Kapiglucagon has the potential to provide more reliable and practical dual-hormone automated glucose control solutions for patients with Type 1 Diabetes and avoid the long-term health complications of inadequate blood glucose control.
ImmuPharma's vision is to position Kapiglucagon as a key enabling solution for next-generation artificial pancreas technologies. By overcoming the long-standing instability of native glucagon in aqueous formulations, Kapiglucagon offers the potential to deliver a stable, pump-compatible glucagon source, allowing dual-hormone closed-loop systems to operate safely and effectively. Through this innovation, ImmuPharma aims to contribute to a new generation of diabetes care in which artificial pancreas systems can significantly reduce the daily burden of disease while improving metabolic control and patient quality of life.
About 505(b)(2) regulatory approval
A 505(b)(2) is a
Kapiglucagon has established a strong scientific rationale and a growing body of supporting CMC and preclinical data, which the Company believes provides a solid foundation for further development. The first step is expected to be a Pre-IND meeting with the FDA to align on the proposed regulatory pathway and the scope of the required CMC, preclinical and clinical program. Following this interaction, the Company intends to advance the remaining development activities, including IND-enabling work, with the objective of entering a focused clinical study designed to generate safety, pharmacokinetic and pharmacodynamic data to support the next stage of value creation for Kapiglucagon.
Glossary
CMC Chemistry, Manufacturing and Controls
CDMO Contract Development and Manufacturing Organisation
FDA U.S. Food and Drug Administration
IND Investigational New Drug
NDA New Drug Application
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.
It is important for you to know that:
(a) none of the Content is, or is intended to be, general or personal advice
(b) the principal purpose of the Content is to provide factual information only and to comment on news;
(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;
(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and
(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.
In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.
FOR OUR FULL DISCLAIMER CLICK HERE